Methods Matter -- Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors
Open accessPreprint — published as 10.1016/j.omtm.2020.05.018 · Paper page
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Different manufacturing approaches have been used in the production of recombinant adeno-associated virus (rAAV). The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Sf9 insect cells. Unexplained differences in vector performance have been seen clinically and preclinically. Thus, we performed for the first time a highly controlled comparative production analysis varying only the host cell species but keeping all other rAAV production parameters the same. We demonstrate that host cell species is critical for determining vector potency. Given these key findings, we then sought to deeply characterize differences in rAAVs when produced by these two manufacturing platforms with multiple analytical approaches including: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM, denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and comparative functional transduction assessments in vitro and in vivo , including in humanized liver mice. Using these tools we’ve made two major discoveries: 1) rAAV capsids have post-translational modifications (PTMs) including glycosylation, acetylation, phosphorylation, methylation and deamidation, and these PTMs differ between platforms; 2) rAAV genomes are methylated during production, and these methylation marks are also differentially deposited between platforms. In addition, our data also demonstrate that host cell protein impurities differ between platforms and can have their own PTMs including potentially immunogenic N-linked glycans. We show that human-produced rAAVs are more potent than baculovirus- Sf9 vectors in various cell types in vitro ( P < 0.05-0.0001), in various mouse tissues in vivo ( P < 0.03-0.0001), and in human liver in vivo ( P < 0.005). Collectively, our findings were reproducible across vendors, including commercial manufacturers, academic core facilities, and individual laboratory preparations. These vector differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity as well as cost considerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 3 Packaged rAAV Genomes Are Methylated during Production and Differentially Methylated Based on the Manufacturing Platform The five tracks of the Circos plot from the outside-in represent the following. First, a schematic of the ssAAV8 genome sequenced with key features labeled is shown (inverted terminal repeat [ITR], orange; intervening sequences, gray; EF1α promoter, red; firefly luciferase expression cassette, blue; woodchuck hepatitis virus posttranscriptional regulatory element [WPRE], plum; human growth hormone polyadenylation signal [hGHpA], magenta). Second, in blue, the methylation ratios for all detected sites for baculovirus-Sf9-produced rAAV8 are shown; the plotting represents a minimum of 0 and a maximum of 1 in 0.1 increments. Third, in red, the methylation ratios for all detected sites for human-produced rAAV are shown; scale same as previous. Fourth, in blue, the total numbers of reads at detected sites for baculovirus-Sf9 produced rAAV8 are shown; in log2 scale, from a minimum of 0 (total reads of 1) to a maximum of 11 (total reads of 211), in 0.1 increments. Fifth, in red, the total numbers of reads at detected sites for human-produced rAAV are shown; scale same as previous. The three sites with statistically significant differential methylation are highlighted in green (C:1208, C:2970, C:3779).](https://figures.cochat.ai/paper-figures/78bbfdddd3c14dd6ad0c41c22c28e3ac/methods-matter-standard-production-platforms-for-recombinant-aav-produce-figure-3.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It showed that the rAAV capsids can have post-translational modifications, such as glycosylation, that depend on the species origin of the production cell.”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rAAVs produced in a human cell line (HEK293T) compared to baculovirus-Sf9 produced rAAVs were more potent in transfecting the liver in mice in vivo and in vitro (HEK293T, Huh7, human induced Pluripotent Stem Cells (hiPSCs), primary human fibroblasts, mouse C2C12 cells).”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“The rAAV production cell line and production cell line related impurities can influence the transduction efficiency in target tissue [44] (Sections 2 and 4.4).”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Circos: An information aesthetic for comparative genomics
Krzywinski, M., Schein, J., Birol, İ., Connors, J., Gascoyne, R., Horsman, D., Jones, S. J., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 10,964
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
ImageJ2: ImageJ for the next generation of scientific image data
Rueden, C. T., Schindelin, J., Hiner, M. C., DeZonia, B. E., Walter, A. E., Arena, E. T., & Eliceiri, K. W. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1934-z · Cited by 5,980
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Research works printed but not linked: 3
- https://investors.biomarin.com/2019-01-07-BioMarin-Highlights-Key-Milestones-for-2019-at-37th-Annual-J-P-Morgan-Healthcare-Conference-in-San-Francisco.
- https://www.pfizer.com/news/press-release/press-release-detail/sangamo_and_pfizer_announce_phase_1_2_interim_data_for_investigational_hemophilia_a_gene_therapy.
- 2013, Phenix.real_space_refine, Computational Crystallography Newsletter, 4, 43
Cited by
Items 101–169 of 169
Wang, F., Sun, J., Guo, W., & Wu, Y. (2024) · Applied Sciences · doi:10.3390/app142310948 · Cited by 7
Native Digestion and Shotgun Proteomics for Host Cell Protein Profiling of Adeno-Associated Viruses
Lodge, J. M., Huang, L., Lian, Z., Qian, J., & Tian, Y. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00893 · Cited by 6
Selective Enrichment of Full Capsids of Adeno-Associated Virus
Bal, V., Wolfrum, J. M., Barone, P. W., Springs, S. L., Sinskey, A. J., Kotin, R. M., & Braatz, R. D. (2025) · ACS Nano · doi:10.1021/acsnano.5c00566 · Cited by 6
Yu, Q., Chang, P., Liu, X., Lü, P., Tang, Q., Guo, Z., Qiu, J., Chen, K., & Yao, Q. (2021) · Viruses · doi:10.3390/v13040704 · Cited by 6
The functional role of the hemoglobin-water interface
Meuwly, M., & Karplus, M. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101042 · Cited by 6
Leibiger, T. M., Min, L., & Lee, K. H. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101623 · Cited by 5
Production of VP3-only virus-like particles of Adeno-associated virus 2 in E. coli cells
Fu, C., Gobbooru, S., Martino, A. T., & Low, W. (2024) · Protein Expression and Purification · doi:10.1016/j.pep.2024.106502 · Cited by 4
Ismail, A. M., Witt, E., Bouwman, T., Clark, W. T., Yates, B., Franco, M., & Fong, S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101294 · Cited by 4
Li, X., Gu, J., Wu, H., & Xie, Y. (2024) · Virology Journal · doi:10.1186/s12985-024-02550-4 · Cited by 4
Application and research progress of MultiBac: A review
Feng, Z., Gao, J., Jiang, C., & Li, Y. (2024) · Medicine · doi:10.1097/md.0000000000039333 · Cited by 3
Kopein, D., Poroshin, G. N., & Авгатович, Х. Р. (2025) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2025-580 · Cited by 3
Development of LC-MS methods for AAV capsid protein quantification and host cell protein profiling
Kontogiannis, T., McElroy, C., Quaglia, M., Foy, C. A., Whale, A. S., Braybrook, J. H., & Smales, C. M. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101562 · Cited by 3
The Application of DNA Viruses to Biotechnology
Schieferecke, A. J., Ralph, N. K., & Schaffer, D. V. (2025) · Viruses · doi:10.3390/v17030414 · Cited by 3
Zhu, X., Yang, K., Xie, J., Feng, X.-L., Wu, T., Hu, M., Wang, H., Yu, C., Yu, X., Hemmatzadeh, F., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315921 · Cited by 3
Wang, X.-S., Yang, Z., Pla, A., Ng, M., Zhuang, B., Ahuja, S., Tjoanda, C., Purde, V., Wenzel, S., Marshall, B., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101579 · Cited by 3
High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector
Weger, S. (2022) · Viruses · doi:10.3390/v15010064 · Cited by 3
Luo, N., Chen, X., Li, J., Huynh, D., Li, Y., Ou, L., & Liu, S. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1302648 · Cited by 3
Performance of Cardiotropic rAAV Vectors Is Dependent on Production Method
Rao, R., Farraha, M., Logan, G. J., Igoor, S., Kok, C., Chong, J. J. H., Alexander, I. E., & Kizana, E. (2022) · Viruses · doi:10.3390/v14081623 · Cited by 3
Kurniawan, M. A. S., Baari, M. J., Sabila, L. C., & Amin, R. T. (2025) · Indo J Chem Res · doi:10.30598/ijcr.2025.13-muh · Cited by 2
Kuno, A., Sakaue, H., Koizumi, S., Tomioka, A., Mizukado, S., Yamaguchi, Y., Fukuhara, M., Tsunaka, Y., Kaji, H., & Uchiyama, S. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-06042-4 · Cited by 2
The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective
Rodríguez, L., de Felipe, P., Martín, R., Martínez, J., Ordóñez, D., Rojo, S., Martínez, J. F., Rincón, E., Cejalvo, T., Izquierdo, I., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251372047 · Cited by 2
Parambathu, A. V., Kumar, V., Khanal, O., & Lenhoff, A. M. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201656 · Cited by 2
Leibiger, T. M., Min, L., & Lee, K. H. (2026) · Human Gene Therapy · doi:10.1177/10430342261443799 · Cited by 2
Matsuzaki, Y., Konno, A., Sakamoto, K., Uchida, Y., Terasaki, T., & Hirai, H. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201783 · Cited by 2
Noriega, H. A., Qizhao, W., Yu, D., & Wang, X. S. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1559461 · Cited by 2
Particle Analytics: Comparative Approaches for Analysis of Viral Vectors
Skaripa-Koukelli, I., Raducanu, A., van Haasteren, J., Albrecht, J., Ringler, P., & Machado, A. H. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-28489-2_9 · Cited by 2
Recombinant Adeno-Associated Virus Production, the Beginning of the End of Uncertainty
Xiao, W., & Samulski, R. J. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29207.wxi · Cited by 2
Machine learning-driven Multi-omics for optimizing Biotherapeutic Production
Gurazada, G. (2024) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/fcvh-0228 · Cited by 2
Jin, J., Wang, W., Gao, T., Dai, Y., Tao, L., Ma, Q., Wang, L., Li, X., Chen, H., & Zhou, Y. F. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117112 · Cited by 1
Ohland, P., Ferreiro, M., Schumacher, J., Franken, L. E., McKenzie, C., Steininger, T., Ringler, P., Lauer, M. E., Phichith, D., & Fakhiri, J. (2025) · Journal of Visualized Experiments · doi:10.3791/68646 · Cited by 1
Shen, W., Chen, S., Li, Z., & Yu, W. (2025) · The FASEB Journal · doi:10.1096/fj.202502611rr · Cited by 1
Tsunaka, Y., Fukuhara, M., Shimojo, S., Matsushita, A., Maruno, T., Soth, S., Nishiumi, H., Rocafort, M. A. V., Kuwahara, T., Matsumoto, K., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201700 · Cited by 1
Kuwahara, A. A., Fenton, E. M., Lovejoy, C., Lee, T., Wang, L., Fogarty, M. M., Jung, J., Guo, S.-M., Maynard, L. H., May, A. P., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201183 · Cited by 1
Self-citationLee, M., & Park, J. E. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108906 · Cited by 1
Random Integration Analysis of Recombinant Adeno-Associated Virus 6 Packaged in Sf9 Insect Cells
Zhang, M., Liu, X., & Zhang, C. (2023) · Molecular Biology · doi:10.1134/s0026893323040209 · Cited by 1
Addgene AAV Data Hub: a platform for sharing AAV experimental data
Nasse, J. S., Leeson, R. L., Zirkle, H., Bourges-Waldegg, D., Pyhtila, B. M., & Fan, M. (2023) · Nature Methods · doi:10.1038/s41592-023-01963-3 · Cited by 1
Beaumal, C., Guapo, F., Smith, J., Carillo, S., & Bones, J. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-05874-4 · Cited by 1
Random Integration Analysis of Recombinant Adeno-Associated Virus 6 Packaged in Sf9 Insect Cells
Zhang, M., Liu, X., & Zhang, C. (2023) · Molecular Biology · doi:10.31857/s0026898423040262 · Cited by 1
Engineering inducible cell lines for recombinant Adeno-Associated Virus production
Lee, Z. (2021) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723 · Cited by 1
Joshi, P. R. H., Venereo-Sánchez, A., Chahal, P. S., & Kamen, A. (2020) · doi:10.22541/au.158750380.04327747
Benefits and Shortcomings of Laboratory Model Systems in the Development of Genetic Therapies
Bucher, K., Rodríguez‐Bocanegra, E., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9879
Li, X., Gu, J., Wu, H., & Xie, Y. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010355060250108034118
Di-methylation of a specific arginine in AAV5 capsid proteins
Levine, J., & Lippincott, J. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103891
A packaging-regulated adenoviral vector for rAAV production
Lu, D., Li, R., Liang, Q., Xiao, Z., & Liu, Q. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152326
浮遊HEK293細胞を用いた遺伝子治療用アデノ随伴ウイルスの生産性及び品質の向上に関する研究
椎名, 俊., シイナ, シ., & Shiina, S. (2023) · Terrestrial Environment Research Center (University of Tsukuba) · doi:10.15068/0002008162
Additional file 1 of Engineered nanoparticles promote cardiac tropism of AAV vectors
Switala, L. E., Di, L., Gao, H., Asase, C., Klos, M., Palanivel, R., Fedyukina, D. V., & Maiseyeu, A. (2024) · Figshare · doi:10.6084/m9.figshare.26715526
Virgolini, N. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Moço, P. D. (2023) · eScholarship@McGill (McGill) · doi:10.82308/50772
Optimization of rAAV Manufacturing at the Triple Transfection Step
Sanmiguel, J. (2023) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Yoon, S., & Liang, G. (2026) · Research Square · doi:10.21203/rs.3.rs-8426890/v1
Mateus, T. M., Carvalho, S. B., Alexandre, B. M., Gomes, R. A., & Gomes‐Alves, P. (2026) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2026.03.004
Singh, I., Kumar, A., Chaudhary, A. K., Dalal, J. S., Sharma, A., Sharma, J., Ratn, A., Dhakad, M. S., & Sharma, D. (2026) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203261437332
Le promoteur du gène SLC16A8, une cible thérapeutique pour la Dégénérescence Maculaire liée à l'âge
Thiébault, L. (2022) · theses.fr (ABES) · doi:10.70675/aee789c6z11b3z4486z9441z23a18287c9f5
Leclerc, S., Godefroy, G., Cheve, C., Cioni, O., Robin, C., Mirabella, F., Adjali, O., & Vaillant, J. (2026) · Journal of Physics Photonics · doi:10.1088/2515-7647/ae768c
What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?
Conheady, J., Donohue, N., Bogdanovic, A., Davin, S., Glennon, B., Barron, N., & Smales, C. M. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70260
Ravendran, S., Fammé, S., Noer, M. G., Skov, T. W., Mikkelsen, N. S., Schneller, J. L., Dorset, S. R., Wolff, J. H., Møller, A. M. J., Haslund, D., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201787
Status and future of recombinant adeno‐associated virus vector manufacturing
Agbogbo, F., & Dismuke, D. J. (2026) · Biotechnology Progress · doi:10.1002/btpr.88525
Vera, K., Gajic, I., Kusumanchi, P., Andaluz, A., Pena, G. D., Froelich, C. A., Higgins, E., Johnston, J., & Motevalian, S. P. (2026) · Biotechnology Progress · doi:10.1002/btpr.88542
Radeef, Y. A., Abdullah, Z. A., & Awadh, E. F. A. (2026) · International Journal of Multidisciplinary and Innovative Research · doi:10.58806/ijmir.2026.v3i8n06
Hu, S., Chen, Y., Wu, C., Reuter, W. H., Deng, J., Jia, N., Walsh, N., Bastille, A., Edwards, T. M. E., Hebben, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14081857
Kim, S. J., Lim, S., & Yang, C. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119932
Manz, J., Woernle, J., Hubbuch, J., Deepak, R., Noack, F., & Huellen, F. (2026) · Viruses · doi:10.3390/v18101158
Chen, Q., Bal, M., Howe, G., Whitfield, R., & Nesbeth, D. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201877
Wang, P., Qi, Y., Han, D., Deng, J., Zhu, Z., Chen, P., Zhu, X., Liu, L., Ren, Q., Qiu, Y., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-11275-9
Khairetdinova, A., Artemyev, V., Astakhova, E. A., Ambaryan, S., Pilagov, M., Maznina, A. A., Kakaulina, V. S., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219928
Gene replacement therapy for GRIN disorder
Yan, Y. (2024) · TSpace (University of Toronto)
Shen, W., Liu, S., & Ou, L. (2022) · doi:10.3389/fimmu.2022.1001263.s001
Metadata
- Authors
- Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., Sinn, P., May, A. P., & Paulk, N. K.
- Affiliations
- Stanford University (US)
- University of California, San Francisco (US)
- Chan Zuckerberg Biohub San Francisco (US)
- Cold Spring Harbor Laboratory (US)
- University of Iowa (US)
- Corresponding author
- Paulk, Nicole K.
- ORCID
- Venue
- Molecular Therapy — Methods & Clinical Development
- Publisher
- openRxiv
- Published
- 2019-05-17
- Volume
- 18
- Pages
- 98-118
- ISSN
- 2329-0501 (ISSN-L)
- PMC
- PMC7488757
- OpenAlex
- W3026609212
- Cited by
- 156
- References
- 71
- Citations by year
- 2026: 15 · 2025: 31 · 2024: 27 · 2023: 28 · 2022: 24 · 2021: 23 · 2020: 7 · 2019: 1
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Molecular Therapy — Methods & Clinical Development (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Howard Hughes Medical Institute
- Children's Hospital of Philadelphia
- University of Georgia
- National Institutes of Health (1s10od010786-01, HL51670, CA086862, DK54759)
- University of California, Davis
- University of California, San Francisco
- Holden Comprehensive Cancer Center, University of Iowa (P30-CA086862)
- National Heart, Lung, and Blood Institute (P01HL051670, U01HL145795, P01HL089707)
- National Cancer Institute (U01CA207702, P30CA086862)
- National Institute of General Medical Sciences (F32GM126663)
- National Institute of Allergy and Infectious Diseases (T32AI060537)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK107607, P30DK054759)
- National Institute of Environmental Health Sciences (U01ES032673)
- Genome Center, University of California, Davis (1S10OD010786-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- recombinant adeno-associated virus, transient transfection, post-translational modification, DNA methylation, vector immunogenicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.